Skip to main content
HCPCS Q9992 · Level II · Part B drug

Q9992: buprenorphine extended-release (Sublocade), HCPCS Level II drug code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for Q9992

Billing unit
Greater than 100 MG
Buprenorphine xr over 100 mg
ASP payment limit
$2,060.132
October 2026; -0.4% vs July 2026
Practitioner MUE
1
MAI 2
OPPS status
SI K
APC 9239
NCCI exposure
no PTP pairs
Coverage articles
0
none list this code

TL;DR

HCPCS Q9992 is the Level II code for Injection, buprenorphine extended-release (sublocade), greater than 100 mg, billed per Greater than 100 MG. The Medicare Part B ASP payment limit for October 2026 is $2,060.132 per billing unit, down 0.4% from July 2026. The practitioner MUE allows up to 1 units per date of service (MAI 2), so a full 1-unit day is $2,060.13 at the current limit. Under OPPS it carries status indicator K in APC 9239. Q9992 is billed in units of Greater than 100 MG; the quantity administered, the NDC package and the units on the claim must reconcile, which is the check that prevents CARC 16 and 151 returns on this line. Other HCPCS codes whose descriptor names buprenorphine extended-release: Q9991 (billed in units of up to 100 mg); J0577 (Brixadi (weekly dosing) from Braeburn Inc.; billed in units of up to 7 days of therapy). The ASP crosswalk maps 1 NDC to it, sold as Sublocade by Indivior Inc. No current Billing and Coding Article lists Q9992, so coverage follows the FDA label, compendia and any applicable NCD.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for Q9992 at $2,060.132 per Greater than 100 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $2,068.155 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for Q9992
QuarterPayment limitPerCoinsurance
October 2026$2,060.132Greater than 100 MG20%
July 2026$2,068.155Greater than 100 MG—
Source: CMS Medicare Part B Drug Payment Limit File. Commercial and Medicaid payers set their own rates.

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 1 NDC from 1 labeler to Q9992. Report the NDC in the claim's drug segment and bill the number of Q9992 units that equals the quantity administered divided by Greater than 100 MG; the last column gives units per full package.

NDCs that crosswalk to Q9992
NDCDrug nameLabelerPackage sizeBilling units / package
12496-0300-01SublocadeIndivior Inc.1.5 × 11

Medically Unlikely Edits (MUE)

CMS publishes 2 MUE values for Q9992. For practitioners the limit is 1 unit per date of service with adjudication indicator 2, a date-of-service policy edit: the limit reflects CMS policy and units above it deny even if split across lines; appeals rarely succeed.

MUE values for Q9992 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services12 Date of Service Edit: PolicyCode Descriptor / CPT Instruction
Facility outpatient hospital12 Date of Service Edit: PolicyCode Descriptor / CPT Instruction

MUE for Q9992 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists Q9992 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check Q9992 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

Q9992 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

No current Billing and Coding Article lists Q9992 in its HCPCS table. Coverage then follows the drug's FDA label, compendia and any National Coverage Determination; check the Medicare Coverage Database before administering off-label.

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, Q9992 carries status indicator K and is assigned to APC 9239, with a published national unadjusted payment of $2,060.132. Status K means the drug is paid separately under OPPS at the ASP-based rate rather than packaged into the procedure.

Ambulatory surgical center (ASC) payment

In the October 2026 ASC Addendum BB (covered ancillary services), Q9992 carries payment indicator K2, which CMS defines as "Drugs, biologicals, and radiopharmaceuticals paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS rate". The national ASC payment is $2,060.13 per Greater than 100 MG, paid only when the drug is furnished integral to a covered surgical procedure.

Common denials for Q9992 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for Q9992

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS Q9992

What does HCPCS code Q9992 describe?

Q9992 is defined by CMS as "Injection, buprenorphine extended-release (sublocade), greater than 100 mg". Each billing unit represents Greater than 100 MG, so the units reported on the claim must equal the dose administered divided by that unit.

Is Q9992 a CPT code?

No. Q9992 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as buprenorphine extended-release (Sublocade); CPT codes are five-character codes maintained by the AMA. On a Part B claim Q9992 reports the drug itself in greater than 100 mg units, and the administration is billed on its own line.

What is the Medicare reimbursement for Q9992 in October 2026?

The ASP-based payment limit is $2,060.132 per Greater than 100 MG, with 20% beneficiary coinsurance. The July 2026 limit was $2,068.155. Commercial payers use their own fee schedules.

How many units of Q9992 can be billed per day?

The practitioner Medically Unlikely Edit is 1 units per date of service with adjudication indicator 2 (Date of Service Edit: Policy). MAI 2 edits are policy limits and are rarely overturned on appeal. CMS cites "Code Descriptor / CPT Instruction" as the rationale.

Which NDCs map to Q9992?

The October 2026 ASP crosswalk lists 1 NDC from 1 labeler: Sublocade (Indivior Inc.). For example NDC 12496-0300-01 (package size 1.5) equals 1 billing unit of Q9992.

Does Q9992 have NCCI bundling edits?

No active practitioner PTP pairs list Q9992 as a column-1 or column-2 code in the v323r0 release.

Q9992 vs Q9991: what is the difference?

Both are HCPCS Level II codes whose descriptor names buprenorphine extended-release. What sets Q9991 apart: billed in units of up to 100 mg. Q9992 is billed per greater than 100 mg, limit $2,060.132, MUE 1; Q9991 is billed per less than or equal to 100 mg, limit $2,060.132, MUE 1. Report the code whose descriptor matches the product and setting in the record.

Q9992 vs J0577: what is the difference?

Both are HCPCS Level II codes whose descriptor names buprenorphine extended-release. What sets J0577 apart: Brixadi (weekly dosing) from Braeburn Inc.; billed in units of up to 7 days of therapy. Q9992 is billed per greater than 100 mg, limit $2,060.132, MUE 1; J0577 is billed per less than or equal to 7 days of therapy, limit $433.167, MUE 1. Report the code whose descriptor matches the product and setting in the record.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.